The Mylan Corporation has been under investigation by the U.S. government since August, when it first came under scrutiny for jacking up the price of the EpiPen from $100 in 2008 to more than $600. After former U.S. presidential candidate Hillary Clinton shone a spotlight on Mylan, its chief executive officer Heather Bresch was called before Congress, with Massachusetts Sen. Elizabeth Warren accusing the pharma boss of employing business tactics meant to keep costs unreasonably high.